Empowering gene therapy development with Countagen’s disruptive gene editing validation technology
| Reference number | |
| Coordinator | Countagen AB |
| Funding from Vinnova | SEK 300 000 |
| Project duration | January 2025 - October 2025 |
| Status | Ongoing |
| Venture | Global cooperation 2024 |
| Call | Planning grant for international proposal 2024 |
Purpose and goal
The aim of the planning project is to develop an application to the EIC Accelerator to secure funding for our breakthrough gene-editing validation technology.
Expected effects and result
The expected outcome of the project is that we develop and submit a competitive EIC Accelerator application and get invited to the panel interview. The expected outcome is that the project will be funded so that we can develop and launch our advanced gene-editing validation technology.
Planned approach and implementation
The project is divided into four work packages: 1. Short proposal development 2. Detailed planning of the project work packages, partnerships, & budget 3. Business plan, commercialisation strategy, competitor analysis and IP 4. Production of a competitive EIC proposal in line with call requirements